Lupeng Pharma Closes $35 Million Pre-B Funding for Novel Drugs
publication date: Jul 30, 2021
Guangzhou Lupeng Pharmaceutical completed a $35 million pre-B financing led by Temasek. The company will use the funds for global clinical development of its lead drug, a selective Bcl-2 inhibitor, along with advancing at least four other candidates into clinical trials. Founded in 2018, Lupeng aims to develop global best-in-class therapies. The company develops novel small molecule drugs for cancer, hepatitis B and autoimmune diseases. Lupeng is approved to conduct clinical trials of its lead Bcl-2 inhibitor in China, the US, the UK and Spain for advanced lymphoma indications. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.